Brief: MEI Pharma, Kyowa Kirin Announce Publication Of Data From Phase 1B Clinical Study Of Zandelisib
18/07/2022 13:46
July 18 (Reuters) - Kyowa Kirin Co Ltd 4151.T :
* MEI PHARMA AND KYOWA KIRIN ANNOUNCE PUBLICATION IN THE
LANCET
ONCOLOGY OF DATA FROM PHASE 1B CLINICAL STUDY OF ZANDELISIB IN
PATIENTS WITH RELAPSED OR REFRACTORY B-CELL MALIGNANCY
Source text for Eikon: ID:nBwW4m6la
Further company coverage: 4151.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kyowa Kirin
See all newsFactbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Factbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Brief: Kyowa Kirin Announces Agreement With US Administration To Reduce Treatment Costs For Americans
Table: Kyowa Kirin 6-MTH group results (IFRS)
Brief: Kyowa Kirin Says European Commission Approves Crysvita For Infants With X-Linked Hypophosphataemia